Colonics
About Me
Recent Posts
- 'Personality Genes' May Help Account For Longevity
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2381
Last Page | Next Page
8/15/2010
-
Merck KGaA, FDA Grants Priority Review To Cladribine Tablets For The Treatment Of Relapsing Forms Of Multiple Sclerosis
|
Merck KGaA announced that the U.S. Food and Drug supervision (FDA) has accepted for filing the New Drug form (NDA) for Cladribine Tablets as a therapy for relapsing forms of voluminous sclerosis (MS). The form also has been granted a order Review designation by the FDA, which means the review period for the NDA is reduced. The goal for corresponding a order Review is six months instead of the mark ten months. prerogative Review is applied to drugs that have the practicable to provide meaning advances in treatment. A decision by the FDA is expected in Q4 2010...
More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
